<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83882">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01780649</url>
  </required_header>
  <id_info>
    <org_study_id>08 117 01</org_study_id>
    <secondary_id>Ministry of Health, PHRC N</secondary_id>
    <nct_id>NCT01780649</nct_id>
  </id_info>
  <brief_title>Evaluation of IMSI to Treat Male Infertility</brief_title>
  <acronym>PHRC-IMSI</acronym>
  <official_title>Evaluation of the Efficiency and Indications of IMSI in Comparison With ICSI in Case of Male Infertility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intracytoplasmic Morphologically Selected Sperm (IMSI) is a modification of IntraCytoplasmic
      Sperm Injection (ICSI) with a choice of the spermatozoon to be injected done at a 6000x
      magnification instead of 400x commonly used in ICSI. The purpose of this study is to
      evaluate the efficiency and the indications of IMSI through a multicentric randomised trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intracytoplasmic sperm injection (ICSI) is largely used to treat male infertility. Usually,
      choice of the spermatozoon to be injected is done at a 400x magnification. Recently, a new
      microscopic technic (Intracytoplasmic Morphologically Selected Sperm Injection-IMSI) allows
      to make this choice at a 6000x magnification, which permits to identify sperm abnormalities
      such as nuclear vacuoles not seen in conventional ICSI. This selection may improve ICSI
      outcome. However only few data from randomised trials, have been published and the
      indications of IMSI remain to be identified. The present study aims to evaluate the
      efficiency and the indications of IMSI through a multicentric randomised trial. The patients
      enrolled in the study must present a male infertility and will have complete sperm
      examination, including morphology, DNA fragmentation and nuclear immaturity. The main
      endpoint will be the percentage of delivery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Delivery</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of fetal heart beat/ number of transferred embryos</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">255</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>IMSI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intracytoplasmic Morphologically Selected Sperm Injection (IMSI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ICSI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intracytoplasmic sperm injection (ICSI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IMSI</intervention_name>
    <description>Intracytoplasmic Morphologically Selected Sperm Injection (IMSI) is a modification of IntraCytoplasmic Sperm Injection (ICSI) with a choice of the spermatozoon to be injected done at a 6000x magnification instead of 400x commonly used in ICSI</description>
    <arm_group_label>IMSI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ICSI</intervention_name>
    <description>ICSI is largely choice of the spermatozoon to be injected done at a 400x magnification</description>
    <arm_group_label>ICSI</arm_group_label>
    <other_name>Intracytoplasmic sperm injection (ICSI)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male infertility with less than 1 million of motile spermatozoa recovered after
             gradient preparation and at least 3 millions of sperm cells in the ejaculate

          -  First Assisted reproductive technology (ART) attempt

        Exclusion Criteria:

          -  Female age &gt; 38

          -  Female follicle stimulating hormone (FSH) level &gt; 9
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean PARINAUD, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bagnolet Hospital</name>
      <address>
        <city>Bagnolet</city>
        <zip>93170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laboratoire CLEMENT</name>
      <address>
        <city>Le Blanc-Mesnil</city>
        <zip>93150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laboratoire de Biologie de la Reproduction, Hôpital Jeanne de Flandre</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de génétique et Biologie de la Reproduction CECOS, Hôpital Maison Blanche</name>
      <address>
        <city>Reims</city>
        <zip>51 100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laboratoire de Biologie de la Reproduction CECOS</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cmco-Sihcus</name>
      <address>
        <city>Schiltigheim</city>
        <zip>67303</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH des 4 villes</name>
      <address>
        <city>Sevres</city>
        <zip>92310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 31, 2013</lastchanged_date>
  <firstreceived_date>January 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IMSI</keyword>
  <keyword>ICSI</keyword>
  <keyword>ART Assisted reproductive technology</keyword>
  <keyword>Spermatozoa</keyword>
  <keyword>male infertility</keyword>
  <keyword>vacuoles</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
